“Anti-CD20 antibodies have demonstrated the ability to kill B lymphocytes in animal models and cause malignant cell lysis by activating complement- and antibody-dependent cellular toxicity (ADCC ...

ADCC: Antibody-dependent cellular cytotoxicity; CDC: Complement-dependent cytotoxicity. Ofatumumab shows good efficacy in conditions with low CD20 expression and is approved for relapsed ...

The results from the first human trial of ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of rheumatoid arthritis (RA) have recently been presented. Genovese et al.

CD20 × CD3 bispecific antibodies bind to both CD20 on malignant B cells and CD3 on T cells, bringing them into close proximity, which triggers T cell-mediated killing of the targeted B cells.

Anti-CD20 mAbs evoke three main mechanisms of cell death: complement-dependent cell death (CDC); antibody-dependent cellular cytotoxicity (ADCC); and direct cell death (DCD). [71] Factors that ...

Mechanism of CAR-NK cell-mediated ADCC. Image Credit ... Image Credit: Sino Biological Inc. Immobilized Anti-CD20 (Ro) antibody (Cat#: 68055-H005) can bind human CD64 protein.